Cizzle Biotechnology (LON:CIZ) has taken a critical step toward getting its early lung cancer blood test into UK hospitals, signing a letter of intent with a major diagnostics partner working alongside the NHS. In this interview, Executive Chairman Dr Allan Syms outlines how this move supports the NHS’s early detection strategy, complements their active US licensing model, and accelerates the test’s return to the UK — where the underlying science was first developed.

Cizzle Biotechnology is a UK-based diagnostics developer focused on early-stage cancer detection through its proprietary CIZ1B blood test.#CizzleBiotech #LungCancer #CancerDetection #HealthTech #NHS #BiotechStocks #AIMstocks #CIZ1B #UKhealthcare